- Home
- Industry Reports
- Healthcare
- Pharmaceuticals
- Europe Diabetes Drugs Market – Size, Outlook, Trends and Forecast (2024 – 2032)
Doctors often refer diabetes as diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate, or because the body’s cells do not respond appropriately to insulin or both. Patients with high blood sugar typically experience polyuria (frequent urination), and become increasingly thirsty (polydipsia) and hungry (polyphagia).
Europe Diabetes Drugs Market Segments Size & Growth:
Europe diabetes drugs market size is projected to reach approximately $29 billion by the end of 2024 with a CAGR of close to 6.8% from $22 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Rise in some diabetics, Government Initiatives and Complexities in alternative diabetes therapy. However, Cost sensitivity issues, Lack of awareness among people and Regulatory framework issues are thereby hampering the market growth.
Europe Diabetes Drugs Market Segments Share:
Europe diabetes drugs market is categorised into Drugs which comprise of Insulin Derivatives and Oral Diabetic Medication Drugs. By Drugs, Oral Diabetic Medication Drugs segment is expected to hold the most significant share in the market. By Geography, UK is projected to dominate the market with the most significant share and the growth in the Europe economies is mainly attributed because of huge profit margins and growth prospects.
Europe Diabetes Drugs Market Trends:
- Novo Nordisk is working on Degludec and DegludecPlus as acceptable long-acting choices. It is longer acting and improves blood glucose levels with a lower risk of hypoglycemia, especially during the nighttime. It will be more accessible and more flexible with dosing, possibly three times weekly. Degludec will also have a U-200 version, which allows more insulin in a reduced volume for those who require large amounts. DegludecPlus has a fixed dose of mealtime (30% Novolog) and basal (70% Degludec) insulin. Novo-Nordisk was filing for FDA approval for this new insulin in January 2012.
- Echo Therapeutics – The Symphony System. It is a non-needle, non-invasive, wireless trans-dermal continuous glucose monitoring system. The Symphony System uses a biosensor without the need to prick the skin since it is trans-dermal (it is an adhesive patch placed on the surface). FDA has approved it and is showing substantial successes in clinical trials. Testing is being done on hospitalised critical care patients who require multiple finger sticks daily.
Europe Diabetes Drugs Market Research Report:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- The primary market players, such as
- Novo Nordisk
- Eli Lilly and Company
- Sanofi Aventis
- Medtronic
- Novartis
1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 Strong encouragement from the governments
4.1.2 Complexities in alternative diabetic therapies
4.1.3 Rise in the number of diabetics
4.2 Restraints
4.2.1 Cost sensitivity issues
4.2.2 Lack of awareness among people
4.2.3 Regulatory framework issues
4.3 Opportunities
4.3.1 approvals of new drugs such as Canagliflozin and dapagliflozin
4.4 Challenges
4.4.1 Cost sensitivity
4.4.2 Low awareness
4.4.3 Regulatory Framework
4.4.4 Effective Disease Management
5. Europe Diabetes Drugs Market – By Drugs
5.1 Insulin Derivatives
5.1.1 Rapid-acting insulin
5.1.2 Intermediate-acting insulin
5.1.3 Long-acting insulin
5.2 Oral Diabetic Medication Drugs
5.2.1 Sulfonylurea
5.2.2 Metformin
5.2.3 Alpha-Glucosidase inhibitor
5.2.4 Thiazolidinediones
5.2.5 Biguanide
5.2.6 Meglitinides
5.2.7 GPP4-Inhibitors
6. Europe Diabetes Drugs Market – By Country
6.1.Introduction
6.2.Germany
6.3.Italy
6.4. The UK
6.5 Rest of Europe
7. Company Profiles
7.1 Novo Nordisk
7.2 Sanofi
7.3 MSD
7.4 Eli Lilly
7.5 Medtronic
7.6 Novartis
7.7 AstraZeneca
7.8 Xinbai Pharmaceutical
7.9 Wanbang Biopharma
7.10 Halozyme Therapeutics
7.11 Oramed Pharmaceuticals Inc.
7.12 Merck KGaA
7.13 Dongbao Enterprise Group Co., Ltd.
7.14 Biocon
7.15 Boehringer Ingelheim
8. Europe Diabetes Drugs Market – Competitive Landscape
8.1 Market Share Analysis
8.2 Strategies Adopted by top companies
8.3 Mergers, Acquisitions, Collaborations & Agreements
9. Market Insights
9.1 Insights of Industry Experts
9.2 Investment Opportunities
9.3 Analyst Opinion
10. Appendix
10.1 List of Tables
10.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Regional Report
$2,160.00 – $7,200.00
- EUR: €1,991.88 - €6,639.62
- INR: ₹180,043.09 - ₹600,143.64
- AED: د.إ7,927.20 - د.إ26,424.00
- GBP: £1,706.75 - £5,689.16
Description
Regional Reports
Additional information
Report Type | Extensive Report, Miniature report, Snapshot Report |
---|---|
Licence | Single User License, Team License, Corporate License |
Doctors often refer diabetes as diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate, or because the body’s cells do not respond appropriately to insulin or both. Patients with high blood sugar typically experience polyuria (frequent urination), and become increasingly thirsty (polydipsia) and hungry (polyphagia).
Europe Diabetes Drugs Market Segments Size & Growth:
Europe diabetes drugs market size is projected to reach approximately $29 billion by the end of 2024 with a CAGR of close to 6.8% from $22 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Rise in some diabetics, Government Initiatives and Complexities in alternative diabetes therapy. However, Cost sensitivity issues, Lack of awareness among people and Regulatory framework issues are thereby hampering the market growth.
Europe Diabetes Drugs Market Segments Share:
Europe diabetes drugs market is categorised into Drugs which comprise of Insulin Derivatives and Oral Diabetic Medication Drugs. By Drugs, Oral Diabetic Medication Drugs segment is expected to hold the most significant share in the market. By Geography, UK is projected to dominate the market with the most significant share and the growth in the Europe economies is mainly attributed because of huge profit margins and growth prospects.
Europe Diabetes Drugs Market Trends:
- Novo Nordisk is working on Degludec and DegludecPlus as acceptable long-acting choices. It is longer acting and improves blood glucose levels with a lower risk of hypoglycemia, especially during the nighttime. It will be more accessible and more flexible with dosing, possibly three times weekly. Degludec will also have a U-200 version, which allows more insulin in a reduced volume for those who require large amounts. DegludecPlus has a fixed dose of mealtime (30% Novolog) and basal (70% Degludec) insulin. Novo-Nordisk was filing for FDA approval for this new insulin in January 2012.
- Echo Therapeutics – The Symphony System. It is a non-needle, non-invasive, wireless trans-dermal continuous glucose monitoring system. The Symphony System uses a biosensor without the need to prick the skin since it is trans-dermal (it is an adhesive patch placed on the surface). FDA has approved it and is showing substantial successes in clinical trials. Testing is being done on hospitalised critical care patients who require multiple finger sticks daily.
Europe Diabetes Drugs Market Research Report:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- The primary market players, such as
- Novo Nordisk
- Eli Lilly and Company
- Sanofi Aventis
- Medtronic
- Novartis
1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 Strong encouragement from the governments
4.1.2 Complexities in alternative diabetic therapies
4.1.3 Rise in the number of diabetics
4.2 Restraints
4.2.1 Cost sensitivity issues
4.2.2 Lack of awareness among people
4.2.3 Regulatory framework issues
4.3 Opportunities
4.3.1 approvals of new drugs such as Canagliflozin and dapagliflozin
4.4 Challenges
4.4.1 Cost sensitivity
4.4.2 Low awareness
4.4.3 Regulatory Framework
4.4.4 Effective Disease Management
5. Europe Diabetes Drugs Market – By Drugs
5.1 Insulin Derivatives
5.1.1 Rapid-acting insulin
5.1.2 Intermediate-acting insulin
5.1.3 Long-acting insulin
5.2 Oral Diabetic Medication Drugs
5.2.1 Sulfonylurea
5.2.2 Metformin
5.2.3 Alpha-Glucosidase inhibitor
5.2.4 Thiazolidinediones
5.2.5 Biguanide
5.2.6 Meglitinides
5.2.7 GPP4-Inhibitors
6. Europe Diabetes Drugs Market – By Country
6.1.Introduction
6.2.Germany
6.3.Italy
6.4. The UK
6.5 Rest of Europe
7. Company Profiles
7.1 Novo Nordisk
7.2 Sanofi
7.3 MSD
7.4 Eli Lilly
7.5 Medtronic
7.6 Novartis
7.7 AstraZeneca
7.8 Xinbai Pharmaceutical
7.9 Wanbang Biopharma
7.10 Halozyme Therapeutics
7.11 Oramed Pharmaceuticals Inc.
7.12 Merck KGaA
7.13 Dongbao Enterprise Group Co., Ltd.
7.14 Biocon
7.15 Boehringer Ingelheim
8. Europe Diabetes Drugs Market – Competitive Landscape
8.1 Market Share Analysis
8.2 Strategies Adopted by top companies
8.3 Mergers, Acquisitions, Collaborations & Agreements
9. Market Insights
9.1 Insights of Industry Experts
9.2 Investment Opportunities
9.3 Analyst Opinion
10. Appendix
10.1 List of Tables
10.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Our Clientele
Exclusive Benefits
Credibility and Transparency
We actively recruit consumers, business professionals, and hard-to-reach individuals as members of our research panels, and we build trusted, ongoing relationships with them. Thus we provide the complete list of primary and secondary data sources in the report to maintain the transparency and to assure the credibility.
Exhaustive Coverage
Detailed and extensive coverage in the geography.Survey consultation for brand tracking, concept testing, consumer behaviour, and more, we have you covered with market research services that scale to meet your needs.
Competitive Edge
Our reports cover most recent updates in the market till the date of the purchase. We identify, gather and timely deliver analysis on impact of unprecedented decisions of CXOs in COVID-19 catastrophe on many businesses, their clients and their clients' clients without additional cost.
Golden Opportunities
A comprehensive strategic sieve analysis of the market by our analysts and consultants, aided by AI tools helps us find the non-obvious, golden and emerging opportunities for you to evaluate.
Top-notch Reports Guaranteed
70% of our research is exclusive; no other research firm has the depth and breadth of our research.
Post Purchase Support
Post-purchase support is provided for all our reports, for three months from the date of purchase, where related queries will be answered within 24 business hours over telephone or email.